Clinical Trial Update: Multiple Dose Study of UCB4940 as add-on to Certolizumab Pegol in Subjects With Rheumatoid Arthritis [Phase 2]

View source ↗

Summary

Phase 2 trial update investigating UCB4940 as an add-on to certolizumab pegol in rheumatoid arthritis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Certolizumab pegol (certolizumab pegol)
• UCB4940

Snippet

Sponsor: UCB Celltech | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED